Biomarkers in Acute Kidney Injury

Critical Care Clinics

Volumn 31, Issue 4, 2015, Pages 633-648

  Chen, Ling Xin ^a   Koyner, Jay L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute kidney injury; Biomarkers; Mortality; Renal replacement therapy

Indexed keywords

ACETYLGLUCOSAMINIDASE; BINDING PROTEIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; ERYTHROPOIETIN; INTERLEUKIN 18; LIVER TYPE FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; SOMATOMEDIN BINDING PROTEIN; TIMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DIALYSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; EMERGENCY WARD; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; RISK ASSESSMENT; SEPSIS; URINE VOLUME; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; ALBUMINURIA; AZOTEMIA; BLOOD; CARDIOVASCULAR SURGERY; COMPLICATION; EMERGENCY HEALTH SERVICE; PATHOPHYSIOLOGY; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ALBUMINURIA; AZOTEMIA; BIOMARKERS; CARDIOVASCULAR SURGICAL PROCEDURES; CREATININE; CYSTATIN C; EARLY DIAGNOSIS; EMERGENCY SERVICE, HOSPITAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERLEUKIN-18; LIPOCALINS; PROTO-ONCOGENE PROTEINS; SEPSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84942193948     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2015.06.002     Document Type: Review

References (97)

1. Bagshaw S.M., Mortis G., Doig C.J., et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis 2006, 48:402-409.
2. Liangos O., Wald R., O'Bell J.W., et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006, 1:43-51.
3. Palevsky P.M. Epidemiology of acute renal failure: the tip of the iceberg. Clin J Am Soc Nephrol 2006, 1:6-7.
4. Srisawat N., Sileanu F.E., Murugan R., et al. Variation in risk and mortality of acute kidney injury in critically ill patients: a multicenter study. Am J Nephrol 2015, 41:81-88.
5. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
6. Chertow G.M., Burdick E., Honour M. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370.
7. Hoste E.A., Clermont G., Kersten A. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10:R73.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012, 2:1-138.
9. Singbartl K., Kellum J.A. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012, 81(9):819-825.
10. Baum N., Dichoso C.C., Carlton C.E. Blood urea nitrogen and serum creatinine: physiology and interpretations. Urology 1975, 5:583-588.
11. Ducharme M.P., Smythe M., Strohs G. Drug-induced alterations in serum creatinine concentrations. Ann Pharmacother 1993, 27:622-633.
12. American Society of Nephrology The American Society of Nephrology renal research report. J Am Soc Nephrol 2005, 16:1886-1903.
13. Koyner J.L., Parikh C.R. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol 2013, 8:1034-1042.
14. Waikar S.S., Betensky R.A., Emerson S.C., et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012, 23:13-21.
15. Murray P.T., Mehta R.L., Shaw A., et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 2014, 85:513-521.
16. Endre Z.H., Kellum J.A., Di Somma S., et al. Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 2013, 182:30-44.
17. Okusa M.D., Jaber B.L., Doran P., et al. Physiological biomarkers of acute kidney injury: a conceptual approach to improving outcomes. Contrib Nephrol 2013, 182:65-81.
18. Cruz D.N., Bagshaw S.M., Maisel A., et al. Use of biomarkers to assess prognosis and guide management of patients with acute kidney injury. Contrib Nephrol 2013, 182:45-64.
19. McCullough P.A., Shaw A.D., Haase M., et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 2013, 182:13-29.
20. Charlton J.R., Portilla D., Okusa M.D. A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant 2014, 29(7):1301-1311.
21. Vanmassenhove J., Vanholder R., Nagler E., et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 2013, 28:254-273.
22. Hansen M.K., Gammelager H., Mikkelsen M.M., et al. Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. Crit Care 2013, 17:R292.
23. Hansen M.K., Gammelager H., Jacobsen C.J., et al. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth 2015, 29(3):617-625.
24. Chertow G., Levy E., Hammermeister K., et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998, 104:343-348.
25. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
26. Parikh C.R., Coca S.G., Thiessen-Philbrook H., et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011, 22:1748-1757.
27. Koyner J.L., Garg A.X., Coca S.G., et al. Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 2012, 23:905-914.
28. Shlipak M.G., Coca S.G., Wang Z., et al. Presurgical serum cystatin C and risk of acute kidney injury after cardiac surgery. Am J Kidney Dis 2011, 58:366-373.
29. Coca S.G., Jammalamadaka D., Sint K., et al. Pre-operative proteinuria predicts acute kidney injury in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2012, 143:495-502.
30. Patel U.D., Storti S., Lorenzoni V., et al. Pre-operative serum brain natriuretic peptide and risk of acute kidney injury after cardiac surgery. Circulation 2012, 125:1347-1355.
31. Coca S.G., Garg A.X., Thiessen-Philbrook H., et al. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol 2014, 25(5):1063-1071.
32. Zappitelli M., Krawczeski C.D., Devarajan P., et al. Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery. Kidney Int 2011, 80:655-662.
33. Spahillari A., Parikh C.R., Sint K., et al. Serum cystatin C- versus creatinine-based definitions of acute kidney injury following cardiac surgery: a prospective cohort study. Am J Kidney Dis 2012, 60:922-929.
34. Parikh C.R., Thiessen-Philbrook H., Garg A.X., et al. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 2013, 8:1079-1088.
35. Bagshaw S.M., Uchino S., Bellomo R., et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007, 2:431-439.
36. Endre Z.H., Pickering J.W., Walker R.J., et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011, 79:1119-1130.
37. Endre Z.H., Walker R.J., Pickering J.W., et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-1030.
38. McIlroy D.R., Wagener G., Lee H.T. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010, 5:211-219.
39. Koyner J.L., Vaidya V.S., Bennett M.R., et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010, 5:2154-2165.
40. Siew E.D., Ware L.B., Bian A., et al. Distinct injury markers for the early detection and prognosis of incident acute kidney injury in critically ill adults with preserved kidney function. Kidney Int 2013, 84:786-794.
41. Siew E.D., Ikizler T.A., Gebretsadik T., et al. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol 2010, 5:1497-1505.
42. Martensson J., Bell M., Oldner A. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010, 36:1333-1340.
43. Tu Y., Wang H., Sun R., et al. Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail 2014, 36:1559-1563.
44. de Geus H.R., Fortrie G., Betjes M.G., et al. Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients. BMC Nephrol 2013, 14:273.
45. Kashani K., Al-Khafaji A., Ardiles T., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013, 17:R25.
46. Hoste E.A., McCullough P.A., Kashani K., et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 2014, 29:2054-2061.
47. Bihorac A., Chawla L.S., Shaw A.D., et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014, 189:932-939.
48. Kellum J.A., Chawla L.S. Cell-cycle arrest and acute kidney injury: the light and the dark sides. Nephrol Dial Transplant 2015, [Epub ahead of print].
49. Koyner J.L., Shaw A.D., Chawla L.S., et al. Tissue inhibitor metalloproteinase-2 (TIMP-2) IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol 2015, 26:1747-1754.
50. Lin C.Y., Chang C.H., Fan P.C., et al. Serum interleukin-18 at commencement of renal replacement therapy predicts short-term prognosis in critically ill patients with acute kidney injury. PLoS One 2013, 8:e66028.
51. Srisawat N., Murugan R., Lee M., et al. Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia. Kidney Int 2011, 80:545-552.
52. Pipili C., Ioannidou S., Tripodaki E.S., et al. Prediction of the renal replacement therapy requirement in mechanically ventilated critically ill patients by combining biomarkers for glomerular filtration and tubular damage. J Crit Care 2014, 29:692.e7-692.e13.
53. Nickolas T.L., O'Rourke M.J., Yang J., et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008, 148:810-819.
54. Nickolas T.L., Schmidt-Ott K.M., Canetta P., et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol 2012, 59:246-255.
55. Haase M., Devarajan P., Haase-Fielitz A., et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011, 57:1752-1761.
56. Soto K., Papoila A.L., Coelho S., et al. Plasma NGAL for the diagnosis of AKI in patients admitted from the emergency department setting. Clin J Am Soc Nephrol 2013, 8:2053-2063.
57. Soto K., Coelho S., Rodrigues B., et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol 2010, 5:1745-1754.
58. Shapiro N.I., Trzeciak S., Hollander J.E., et al. The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. Ann Emerg Med 2010, 56:52-59.
59. Schinstock C.A., Semret M.H., Wagner S.J., et al. Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrol Dial Transplant 2013, 28:1175-1185.
60. Somma Di, Magrini L., De Berardinis B.S., et al. Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013, 17:R29.
61. Parikh C.R., Han G. Variation in performance of kidney injury biomarkers due to cause of acute kidney injury. Am J Kidney Dis 2013, 62:1023-1026.
62. Parikh C.R., Jani A., Melnikov V.Y., et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004, 43:405-414.
63. Han W.K., Bailly V., Abichandani R., et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62:237-244.
64. Nejat M., Pickering J.W., Devarajan P., et al. Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int 2012, 81(12):1254-1262.
65. Doi K., Katagiri D., Negishi K., et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int 2012, 82:1114-1120.
66. Belcher J.M., Parikh C.R. Is it time to evolve past the prerenal azotemia versus acute tubular necrosis classification?. Clin J Am Soc Nephrol 2011, 6:2332-2334.
67. Bellomo R., Bagshaw S., Langenberg C., et al. Pre-renal azotemia: a flawed paradigm in critically ill septic patients?. Contrib Nephrol 2007, 156:1-9.
68. Basu R.K., Wong H.R., Krawczeski C.D., et al. Combining functional and tubular damage biomarkers improves diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol 2014, 64:2753-2762.
69. Koyner J.L., Davison D.L., Brasha-Mitchell E., et al. Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol 2015, [Epub ahead of print].
70. Faubel S., Chawla L.S., Chertow G.M., et al. Ongoing clinical trials in AKI. Clin J Am Soc Nephrol 2012, 7:861-873.
71. Smith O.M., Wald R., Adhikari N.K., et al. Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial. Trials 2013, 14:320.
72. Srisawat N., Tiranathanagul K., Susantitaphong P., et al. The effect of early intervention with renal replacement therapy guiding by plasma neutrophil gelatinase associated lipocalin and the outcome of acute kidney injury (the EARLYRRT trial): a randomized controlled trial. J Am Soc Nephrol 2014, 25:7A. [Abstract TH-OR029].
73. Chawla L.S., Eggers P.W., Star R.A., et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014, 371:58-66.
74. Zhang Z., Lu B., Sheng X., et al. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis 2011, 58:356-365.
75. Herget-Rosenthal S., Bökenkamp A., Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations?. Clin Biochem 2007, 40:153-161.
76. Séronie-Vivien S., Delanaye P., Piéroni L., et al. Cystatin C: current position and future prospects. Clin Chem Lab Med 2008, 46(12):1664-1686.
77. Nejat M., Hill J.V., Pickering J.W., et al. Albuminuria increases cystatin C excretion: implications for urinary biomarkers. Nephrol Dial Transplant 2012, 27:iii96-iii103.
78. Dinarello C.A., Novick D., Kim S., et al. Interleukin-18 and IL-18 binding protein. Front Immunol 2013, 4:289.
79. Melnikov V.Y., Faubel S., Siegmund B., et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 2002, 110:1083-1091.
80. Ichimura T., Bonventre J.V., Bailly V., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998, 273:4135-4142.
81. Bonventre J.V. Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc 2014, 125:293-299.
82. Ichimura T., Brooks C.R., Bonventre J.V. Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int 2012, 81:809-811.
83. Maatman R.G., van de Westerlo E.M., van Kuppevelt T.H., et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992, 288:285-290.
84. Yamamoto T., Noiri E., Ono Y., et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007, 18:2894-2902.
85. Tanaka T., Noiri E., Yamamoto T., et al. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol 2008, 108:e19-e26.
86. Negishi K., Noiri E., Sugaya T., et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007, 72:348-358.
87. Yamashita T., Doi K., Hamasaki Y., et al. Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. Crit Care 2014, 18(6):716.
88. Kjeldsen L., Johnsen A.H., Sengelov H., et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-10432.
89. Haase-Fielitz A., Haase M., Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 2014, 51:335-351.
90. Singer E., Markó L., Paragas N., et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf) 2013, 207:663-672.
91. Martensson J., Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purif 2014, 37:304-310.
92. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11:S37-S43.
93. Tamura K., Hashimoto K., Suzuki K., et al. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells. Eur J Pharmacol 2009, 610:61-67.
94. Mazanowska O., Zabińska M., Kościelska-Kasprzak K., et al. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients. Transplant Proc 2014, 46:2636-2639.
95. Seo D.W., Li H., Qu C.K., et al. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006, 281:3711-3721.
96. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999, 20:761-787.
97. Meersch M., Schmidt C., Van Aken H., et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One 2014, 9:e93460.